Skip to main content

Advertisement

SpringerLink
Log in

Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease

  • Review Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Management of spondyloarthritis (SpA) in patients with inflammatory bowel disease (IBD) remains a challenging task that requires multidisciplinary collaboration. Separate guidelines for each disease are well-established. However, the management of SpA co-occurring with Crohn’s disease (CD) or ulcerative colitis (UC) has hardly been studied. There are few specific reports that focus on this therapeutic area. The main issue is that some therapeutic options used to treat one disease can negatively influence the other disease course. This study aims to evaluate the therapeutic alternatives that would allow for the appropriate management of patients with both SpA and IBD.

Key Points

• Collaboration between gastroenterologists and rheumatologists is recommended to improve the management of patients with spondyloarthritis (SpA) and inflammatory bowel disease (IBD).

• When treating SpA occurring simultaneously with IBD, it would be appropriate to give priority to the active disease.

• Considering its well-proven efficacy in both conditions, anti-tumor necrosis factor (TNF) therapy remains the corner stone in the treatment of these patients.

• Other therapeutic options such as Janus kinases (JAK) inhibitors, interleukin (IL)-23 and IL-12 inhibitors, and vedolizumab are still under investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Brakenhoff LKPM, van der Heijde DM, Hommes DW, Huizinga TWJ, Fidder HH (2010) The joint—gut axis in inflammatory bowel diseases. J Crohns Colitis 4:257–268. https://doi.org/10.1016/j.crohns.2009.11.005

    Article  PubMed  Google Scholar 

  2. Olivieri I, Cantini F, Castiglione F, Felice C, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Vecchi M, Armuzzi A (2014) Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev 13:822–830. https://doi.org/10.1016/j.autrev.2014.04.003

    Article  PubMed  Google Scholar 

  3. Pouillon L, Bossuyt P, Vanderstukken J, Moulin D, Netter P, Danese S, Jouzeau JY, Loeuille D, Peyrin-Biroulet L (2017) Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Rev Clin Pharmacol 10:1363–1374. https://doi.org/10.1080/17512433.2017.1377609

    Article  CAS  PubMed  Google Scholar 

  4. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G (2000) Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 95:1949–1954. https://doi.org/10.1111/j.1572-0241.2000.02262.x

    Article  CAS  PubMed  Google Scholar 

  5. Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ (2006) Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 4:203–211. https://doi.org/10.1016/j.cgh.2005.12.002

    Article  CAS  PubMed  Google Scholar 

  6. El Miedany Y, Youssef S, Ahmed I, El Gaafary M (2006) The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 101:311–317. https://doi.org/10.1111/j.1572-0241.2006.00384.x

    Article  CAS  PubMed  Google Scholar 

  7. Chen J, Lin S, Liu C (2014) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 11. https://doi.org/10.1002/14651858.CD004800.pub3

  8. Wang Y, Parker CE, Feagan BG, MacDonald JK (2016) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev:CD000544. https://doi.org/10.1002/14651858.CD000544.pub4

  9. Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK, Cochrane IBD Group (2016) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 4:CD000543. https://doi.org/10.1002/14651858.CD000543.pub4

    Article  PubMed  Google Scholar 

  10. Gomollón F, Dignass A, Annese V, Tilg H, van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P, on behalf of ECCO (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11:3–25. https://doi.org/10.1093/ecco-jcc/jjw168

    Article  PubMed  Google Scholar 

  11. Lim W-C, Wang Y, MacDonald JK, Hanauer S (2016) Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev 7:CD008870. https://doi.org/10.1002/14651858.CD008870.pub2

    Article  PubMed  Google Scholar 

  12. Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Rizzello F, Gionchetti P (2017) Case-control study on dactylitis, enthesitis, and anterior uveitis in spondyloarthritis associated with inflammatory bowel diseases: role of coexistent psoriasis. J Rheumatol 44:1341–1346. https://doi.org/10.3899/jrheum.161518

    Article  PubMed  Google Scholar 

  13. Zu Hoerste MM, Walscheid K, Tappeiner C et al (2018) The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol 256:1985–1992. https://doi.org/10.1007/s00417-018-4082-x

    Article  CAS  PubMed  Google Scholar 

  14. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A (2000) Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye Lond Engl 14(Pt 3A):340–343. https://doi.org/10.1038/eye.2000.84

    Article  Google Scholar 

  15. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M, Hanauer SB, McDonald JWD (1995) Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 332:292–297. https://doi.org/10.1056/NEJM199502023320503

    Article  CAS  PubMed  Google Scholar 

  16. McDonald JWD, Wang Y, Tsoulis DJ et al (2014) Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev:CD003459. https://doi.org/10.1002/14651858.CD003459.pub4

  17. Carbonnel F, Colombel JF, Filippi J et al (2016) Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology 150:380–388.e4. https://doi.org/10.1053/j.gastro.2015.10.050

    Article  CAS  PubMed  Google Scholar 

  18. Wang Y, MacDonald JK, Vandermeer B et al (2015) Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev:CD007560. https://doi.org/10.1002/14651858.CD007560.pub3

  19. Felice C, Pugliese D, Papparella LG, Pizzolante F, Onori E, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A (2018) Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. Expert Rev Clin Immunol 14:751–759. https://doi.org/10.1080/1744666X.2018.1513329

    Article  CAS  PubMed  Google Scholar 

  20. Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, Sieper J (2007) No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 66:419–421. https://doi.org/10.1136/ard.2006.054098

    Article  CAS  PubMed  Google Scholar 

  21. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H (1984) European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 86:249–266

    Article  CAS  PubMed  Google Scholar 

  22. Summers RW, Switz DM, Sessions JT et al (1979) National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 77:847–869

    Article  CAS  PubMed  Google Scholar 

  23. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO, Cochrane IBD Group (2003) Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev:CD000301. https://doi.org/10.1002/14651858.CD000301

  24. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76:978–991. https://doi.org/10.1136/annrheumdis-2016-210770

    Article  PubMed  Google Scholar 

  25. Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J (2014) Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 73:243–246. https://doi.org/10.1136/annrheumdis-2012-203055

    Article  CAS  PubMed  Google Scholar 

  26. Chande N, Townsend CM, Parker CE, MacDonald JK (2016) Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 10:CD000545. https://doi.org/10.1002/14651858.CD000545.pub5

    Article  PubMed  Google Scholar 

  27. Timmer A, Patton PH, Chande N et al (2016) Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev:CD000478. https://doi.org/10.1002/14651858.CD000478.pub4

  28. Chande N, Patton PH, Tsoulis DJ et al (2015) Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev:CD000067. https://doi.org/10.1002/14651858.CD000067.pub3

  29. Guillot X, Prati C, Sondag M, Wendling D (2017) Etanercept for treating axial spondyloarthritis. Expert Opin Biol Ther 17:1173–1181. https://doi.org/10.1080/14712598.2017.1347156

    Article  CAS  PubMed  Google Scholar 

  30. Bieber A, Fawaz A, Novofastovski I, Mader R (2017) Antitumor necrosis factor-α therapy associated with inflammatory bowel disease: three cases and a systematic literature review. J Rheumatol 44:1088–1095. https://doi.org/10.3899/jrheum.160952

    Article  CAS  PubMed  Google Scholar 

  31. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet Lond Engl 359:1541–1549. https://doi.org/10.1016/S0140-6736(02)08512-4

    Article  CAS  Google Scholar 

  32. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJS, Present D, Sands BE, Colombel JF (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476. https://doi.org/10.1056/NEJMoa050516

    Article  CAS  PubMed  Google Scholar 

  33. Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Danielsson Å, Verbaan H, Hellström PM, Magnuson A, Curman B (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128:1805–1811. https://doi.org/10.1053/j.gastro.2005.03.003

    Article  CAS  PubMed  Google Scholar 

  34. Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, Burisch J, de Vos M, de Vries AM, Dick AD, Juillerat P, Karlsen TH, Koutroubakis I, Lakatos PL, Orchard T, Papay P, Raine T, Reinshagen M, Thaci D, Tilg H, Carbonnel F, for the European Crohn’s and Colitis Organisation [ECCO] (2016) The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 10:239–254. https://doi.org/10.1093/ecco-jcc/jjv213

    Article  PubMed  Google Scholar 

  35. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P, UNITI–IM-UNITI Study Group (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375:1946–1960. https://doi.org/10.1056/NEJMoa1602773

    Article  CAS  PubMed  Google Scholar 

  36. Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381:1201–1214. https://doi.org/10.1056/NEJMoa1900750

    Article  CAS  PubMed  Google Scholar 

  37. Rowan CR, Boland K, Harewood GC (2020) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 382:91. https://doi.org/10.1056/NEJMc1915042

    Article  PubMed  Google Scholar 

  38. McInnes IB, Kavanaugh A, Gottlieb AB et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet Lond Engl 382:780–789. https://doi.org/10.1016/S0140-6736(13)60594-2

    Article  CAS  Google Scholar 

  39. Poddubnyy D, Hermann K-GA, Callhoff J, Listing J, Sieper J (2014) Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 73:817–823. https://doi.org/10.1136/annrheumdis-2013-204248

    Article  CAS  PubMed  Google Scholar 

  40. Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, Zhou Y, Leu JH, Campbell K, Sweet K, Harrison DD, Hsia EC, Heijde D, Ariel F, Asnal CA, Berman A, Citera G, Rodriguez G, Savio VG, Bird P, Griffiths H, Nicholls D, Rischmueller M, Zochling J, de Vlam K, Malaise M, Toukap AN, van den Bosch F, Vanhoof J, Bonfiglioli R, Keiserman M, Scotton AS, Xavier R, Ximenes AC, Atanasov A, Goranov I, Kazmin I, Licheva RN, Nikolov N, Oparanov B, Stoilov R, Bessette L, Rodrigues J, Bortilik L, Dokoupilova E, Dvoarak Z, Galatikova D, Nemec P, Podrazilova L, Simkova G, Stejfova Z, Moravcova R, Vitek P, Cantagrel A, Baillet A, Banneville B, Combe B, Breban M, Nguyen M, Goupille P, Braun J, Everding A, Kekow J, Koenig R, Rubbert-Roth A, Witte T, Bartha A, Drescher E, Kerekes K, Kovacs A, Pulai J, Rojkovich B, Szanto S, Toth E, Avila H, Torre IG, Irazoque F, Maradiaga M, Pacheco C, Brzosko M, Dudek A, Jeka S, Krogulec M, Kwiatkowska B, Wiland P, Wojciechowski R, Zielinska A, Santos H, Bugrova O, Christyakov V, Gorbunov V, Ilivanova E, Zemerova E, Kamalova R, Kameneva T, Macievskaya G, Marusenko I, Maslyansky A, Myasoedova S, Myasoutova L, Nemtsov B, Nesmeyanova O, Plaksina T, Pokrovskaya T, Polyakova S, Rebrov A, Savina L, Smakotina S, Stanislav M, Ukhanova O, Vinogradova I, Zonova E, Baek HJ, Kim TH, Lee CK, Lee SH, Lee SH, Lee SS, Park SH, Song YW, Suh CH, Ramos JA, Blanco FJ, Collantes E, Diaz MC, Vivar MLG, Gratacos J, Juanola X, Chen DY, Chen HC, Chen KH, Chen YC, Chiu YM, Luo SF, Tsai ST, Tseng JC, Wei CC, Weng MY, Abrahamovych O, Reshotko D, Golovchenko O, Hospodarsky I, Iaremenko O, Levchenko O, Dudnyk O, Garmish O, Grishyna O, Protsenko G, Rekalov D, Smiyan S, Stanislavchuk M, Trypilka S, Tseluyko V, Turianytsia S, Vasylets V, Virstyuk N, Kleban Y, Ciurtin C, Gaffney K, Gunasekera W, Mackay K, Packham J, Sengupta R, Tahir H, Aelion J, Bennett R, Deodhar A, Gonzalez-Paoli J, Griffin RM, Grisanti M, Mallepalli J, Peters E, Schechtman J, Singhal A (2019) Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in Axial spondyloarthritis. Arthritis Rheumatol Hoboken NJ 71:258–270. https://doi.org/10.1002/art.40728

    Article  CAS  Google Scholar 

  41. Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376:1723–1736. https://doi.org/10.1056/NEJMoa1606910

    Article  CAS  PubMed  Google Scholar 

  42. van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, Li D, Menon S, Kanik KS (2017) Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 76:1340–1347. https://doi.org/10.1136/annrheumdis-2016-210322

    Article  CAS  PubMed  Google Scholar 

  43. Sandborn WJ, Ghosh S, Panes J et al (2014) A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol 12:1485–1493.e2. https://doi.org/10.1016/j.cgh.2014.01.029

    Article  CAS  PubMed  Google Scholar 

  44. Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E (2017) Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut 66:1049–1059. https://doi.org/10.1136/gutjnl-2016-312735

    Article  CAS  PubMed  Google Scholar 

  45. Ma C, Jairath V, Vande Casteele N (2019) Pharmacology, efficacy and safety of JAK inhibitors in Crohn’s disease. Best Pract Res Clin Gastroenterol 38–39:101606. https://doi.org/10.1016/j.bpg.2019.03.002

    Article  PubMed  Google Scholar 

  46. Blair HA (2019) Secukinumab: a review in ankylosing spondylitis. Drugs 79:433–443. https://doi.org/10.1007/s40265-019-01075-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J, Morin F, Rahman P, Ariel F, Berman A, Carrio J, Lucero E, Cocco JM, Hidalgo RP, Velasco J, Viola DO, Grisar J, Resch H, Scheinecker C, Melazzi AC, Roimicher L, Scotton AS, Rodriguez AAB, Molina FFC, Barragan SD, Skinner CM, Tena CFP, Remus CRR, Rodriguez JCR, Hong SJ, Kang SW, Lee CK, Lee EB, Lee SH, Park MC, Lee SH, Dokoupilova E, Dvorak Z, Malcova M, Pvelka K, Eklund KK, Jarvinen P, Karjalainen A, Paimela L, Taniguchi Y, Tsuda T, Tada K, Dobashi H, Inui K, Ueki Y, Matsumoto Y, Hatta K, Atsumi T, Goto H, Honjo S, Matsui K, Takakubo Y, Neeck G, Wagner S, Braun J, Blicharshi T, Dudek A, Hrycai P, Plebanski R, Drabiszcak-Piatkowska J, Brzezicki J, Krogulec M, Opris-Belinski D, Ramazan AM, Tronaru L, van de Sande MG, Matsievskaya G, Schmidt E, Stanislav M, Yakushin S, Ershova O, Rebroy A, Churchill MA, Flint KP, Greenwald M, Howell MP, Kaine JL, Kivitz A, Klein SJ, Mueller EC, Peters EA, Querubin R, Sayers ME, Scoville CD, Shanahan JC, Roseff R, Hull JE, Mallepalli JR, Sebai MB, Kimmel SC, Goddard DH, Mease PJ, Harris MD, Mabaquiao AR, Diegel RJ, Thai C, Rivera TL, Perez-de Jesus A, Soto-Raices O, Toro-Torres R, Pantojas C (2020) Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet Lond Engl 395:53–64. https://doi.org/10.1016/S0140-6736(19)32971-X

    Article  CAS  Google Scholar 

  48. Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Järvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD, the COAST‐W Study Group, Antolini C, Azevedo V, Barkham M, Rodriguez AAB, Berman A, Blicharski T, Brzezicki J, Burmester G, Carrio J, Collantes E, Combe B, Cons-Molina F, Cortes-Maisonet G, Dudek A, Barragan SD, Elkayam O, Flint K, Galeazzi M, Gaylis N, Goddard D, Fernandez CG, Goupille P, Masmitja JG, Greenwald M, Gremese E, Hong SJ, Howell M, Hrycaj P, Ince A, Ju JH, Kaine J, Kang SW, Keiserman M, Kim TH, Kivitz A, Klein S, Kremer J, Lee SH, Lee CK, Lee SH, Lidman R, Loveless J, Lucero E, Cocco JM, Marcolino F, Mariette X, Mehta D, Morin F, Moscovici Y, Mueller E, Mysler E, Blasco FN, Nguyen M, Pantojas C, Park MC, Jesus APD, Peters E, Plebanski R, Querubin R, Remus CR, Reitblat T, Rivera T, Rodriguez JCR, Sayers M, Scotton A, Scoville C, Shaw D, Shin K, Singhal A, Skinner C, Soto-Raices O, Soubrier M, Szymanska M, Thai C, Sande M, Wells A, Wojciechowski R, Xavier R, Ximenes A, Zisman D (2019) Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol Hoboken NJ 71:599–611. https://doi.org/10.1002/art.40753

    Article  CAS  Google Scholar 

  49. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SPL, for the Secukinumab in Crohn’s Disease Study Group (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61:1693–1700. https://doi.org/10.1136/gutjnl-2011-301668

    Article  CAS  PubMed  Google Scholar 

  50. Achufusi TG, Harnee PS, Rawlins S (2019) A rare case of new-onset ulcerative colitis following initiation of secukinumab. Case Rep Med 2019:2975631–2975635. https://doi.org/10.1155/2019/2975631

    Article  PubMed  PubMed Central  Google Scholar 

  51. Rodríguez Moncada R, Vázquez Morón JM, Pallarés Manrique H (2019) The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease? Rev Espanola Enfermedades Dig 111:720–721. https://doi.org/10.17235/reed.2019.5841/2018

    Article  Google Scholar 

  52. Reich K, Leonardi C, Langley RG et al (2017) Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol 76:441–448.e2. https://doi.org/10.1016/j.jaad.2016.10.027

    Article  CAS  PubMed  Google Scholar 

  53. Armuzzi A, Gionchetti P, Daperno M, Danese S, Orlando A, Lia Scribano M, Vecchi M, Rizzello F, Ardizzone S, Armuzzi A, Castiglione F, Danese S, Daperno M, Fantini M, Fiorino G, Frieri G, Gionchetti P, Neri L, Orlando A, Rizzello F, Lia Scribano M, Carlo Sturniolo G, Vecchi M (2016) Expert consensus paper on the use of vedolizumab for the management of patients with moderate-to-severe inflammatory bowel disease. Dig Liver Dis 48:360–370. https://doi.org/10.1016/j.dld.2015.12.016

    Article  CAS  PubMed  Google Scholar 

  54. Varkas G, Thevissen K, De Brabanter G et al (2017) An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis 76:878–881. https://doi.org/10.1136/annrheumdis-2016-210233

    Article  CAS  PubMed  Google Scholar 

  55. Tamanini S, Fredi M, Crisafulli F, Lazzaroni MG, Tincani A, Franceschini F (2019) Letter to editor: new onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease. Clin Rheumatol 38:609–610. https://doi.org/10.1007/s10067-018-4357-y

    Article  PubMed  Google Scholar 

  56. Orlando A, Orlando R, Ciccia F, Renna S, Rizzo A, Cottone M, Macaluso FS (2017) Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. Ann Rheum Dis 76:e31. https://doi.org/10.1136/annrheumdis-2016-211011

    Article  PubMed  Google Scholar 

  57. Wendling D, Lukas C, Prati C, Claudepierre P, Gossec L, Goupille P, Hudry C, Miceli-Richard C, Molto A, Pham T, Saraux A, Dougados M (2018) Actualisation 2018 des recommandations de la Société française de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite. Rev Rhum 85:222–230. https://doi.org/10.1016/j.rhum.2017.11.009

    Article  Google Scholar 

  58. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L (2019) 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the treatment of ankylosing spondylitis and nonradiographic Axial spondyloarthritis. Arthritis Care Res 71:1285–1299. https://doi.org/10.1002/acr.24025

    Article  Google Scholar 

  59. Rutgeerts PJ (2001) Conventional treatment of Crohn’s disease: objectives and outcomes. Inflamm Bowel Dis 7(Suppl 1):S2–S8. https://doi.org/10.1002/ibd.3780070503

    Article  PubMed  Google Scholar 

  60. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, DʼHaens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, van Assche G, Danese S, Panes J, Bouguen G, OʼDonnell S, Pariente B, Winer S, Hanauer S, Colombel JF (2015) Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110:1324–1338. https://doi.org/10.1038/ajg.2015.233

    Article  CAS  PubMed  Google Scholar 

  61. Danese S, Roda G, Peyrin-Biroulet L (2019) Evolving therapeutic goals in ulcerative colitis: towards disease clearance. Nat Rev Gastroenterol Hepatol 17:1–2. https://doi.org/10.1038/s41575-019-0211-1

    Article  Google Scholar 

  62. Coto P, Riestra S, Rozas P, Señaris A, Queiro R (2020) Improving the standard of care for patients with spondyloarthritis-related immune inflammatory conditions: results of a Delphi study and proposal for early detection. Ther Adv Chronic Dis 11:2040622320904295. https://doi.org/10.1177/2040622320904295

    Article  PubMed  PubMed Central  Google Scholar 

  63. Peña-Sánchez JN, Lix LM, Teare GF, Li W, Fowler SA, Jones JL (2017) Impact of an integrated model of care on outcomes of patients with inflammatory bowel diseases: evidence from a population-based study. J Crohns Colitis 11:1471–1479. https://doi.org/10.1093/ecco-jcc/jjx106

    Article  PubMed  Google Scholar 

  64. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F, for the European Crohn’s and Colitis Organisation [ECCO] (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 11:769–784. https://doi.org/10.1093/ecco-jcc/jjx009

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology Department, Kassab Orthopedics Institute, Mannouba, Tunisia

    Dorra Ben Nessib, Hanene Ferjani, Kaouther Maatallah, Safa Rahmouni, Dhia Kaffel & Wafa Hamdi

  2. Faculty of Medicine of Tunis, University Tunis el Manar, Tunis, Tunisia

    Dorra Ben Nessib, Hanene Ferjani, Kaouther Maatallah, Safa Rahmouni, Dhia Kaffel & Wafa Hamdi

  3. Research Unit UR17SP04, Ksar Said, 2010, Tunis, Tunisia

    Dorra Ben Nessib, Hanene Ferjani, Kaouther Maatallah, Safa Rahmouni, Dhia Kaffel & Wafa Hamdi

Authors
  1. Dorra Ben Nessib
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanene Ferjani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kaouther Maatallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Safa Rahmouni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dhia Kaffel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wafa Hamdi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dorra Ben Nessib.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ben Nessib, D., Ferjani, H., Maatallah, K. et al. Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease. Clin Rheumatol 39, 3543–3553 (2020). https://doi.org/10.1007/s10067-020-05136-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-05136-x

Keywords

Search

Navigation